Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Icatibant (Firazyr) vs Plecanatide (Trulance)
An educational, source-based comparison of Icatibant (Firazyr) and Plecanatide (Trulance) — how each peptide works, what it's researched for, and what to know before going deeper.
Bradykinin B2 receptor antagonist for hereditary angioedema attacks.
Synthetic decapeptide that competitively blocks the bradykinin B2 receptor, halting the vascular leak that drives HAE swelling attacks.
- Hereditary angioedema (acute attacks)
- • FDA-approved.
- • Injection-site reactions very common.
Synthetic analog of human uroguanylin that activates guanylate cyclase-C in a pH-dependent manner, increasing intestinal fluid secretion and transit.
- Chronic idiopathic constipation
- IBS-C
- • FDA-approved.
- • Diarrhea most common adverse event.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Icatibant (Firazyr) | FAST-3 trial | Annals of Allergy | 2011 | Faster symptom relief vs placebo in HAE attacks. |
| Plecanatide (Trulance) | Plecanatide phase 3 | American Journal of Gastroenterology | 2017 | Significantly improved complete spontaneous bowel movements vs placebo. |
Side-effect & safety grid
- FDA-approved.
- Injection-site reactions very common.
- FDA-approved.
- Diarrhea most common adverse event.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Icatibant (Firazyr) vs Plecanatide (Trulance) — Key differences
- Class: Icatibant (Firazyr) is classified as Bradykinin Antagonist · Immunology, while Plecanatide (Trulance) is GC-C Agonist · Gastrointestinal.
- Primary research focus: Icatibant (Firazyr) — hereditary angioedema (acute attacks); Plecanatide (Trulance) — chronic idiopathic constipation.
- Tag: FDA-Approved · Rare Disease vs FDA-Approved · GI.